Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

India's Finance Minister will present the FY25-26 Union Budget on February 1, 2025. Analysts suggest focus on manufacturing, ...

Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...

The market is expected to sustain range-bound trading, and the elevated volatility signals caution for bulls. Below are some ...

The market may extend its upward journey, but sustainability is the key to watch, given the elevated volatility. Below are ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Shaw, Chairperson of Biocon, has urged the government to remove tax on medicines used to treat cancer, chronic illnesses, and ...

China's rural healthcare gap impacts timely medical response; the EU plans to ban 'forever chemicals'; North America eases ...

HYDERABAD, India (Reuters) - India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major drugmaker Biocon Ltd said ahead of Prime Minister ...